The FDA agreed to review AstraZeneca�s $AZN resubmitted New Drug Application (NDA) seeking approval of ZS-9 for the treatment of hyperkalemia (elevated potassium in the blood). The regulatory authority has categorized the refiling as a Class 2 Resubmission, which means it may include a presentation to an advisory panel and requires a re-inspection of its manufacturing facility.